Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals (RYTM)
:RYTM
RYTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$35.17 - $68.58
Previous CloseN/A
Volume91.33K
Average Volume (3M)578.55K
Market Cap
$3.15B
Enterprise Value$3.38B
Total Cash (Recent Filing)-$241.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.11
Next Earnings
May 06, 2025EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.36
Shares Outstanding63,223,730
10 Day Avg. Volume585,817
30 Day Avg. Volume578,553
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)25.28
Price to Cash Flow (P/CF)-43.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.98
Enterprise Value/Ebitda-14.18
Forecast
1Y Price Target
$75.18Price Target Upside44.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessIMCIVREE's Phase 3 trial in hypothalamic obesity is expected to be positive, with high odds of a favorable risk/reward scenario.
Demand ExpectationsExpert endocrinologist Dr. Lewis Blevins expects to use setmelanotide for all of his hypothalamic obesity patients if approved, which indicates strong potential demand.
Market PotentialThe Phase 3 data for setmelanotide in hypothalamic obesity is likely to hit the primary BMI endpoint and unlock a potential >2B total addressable market.
Bears Say
Clinical Trial RiskIMCIVREE’s efficacy on BMI reduction at week 52 in its Phase 3 trial in HO is less than 10% or the trial fails to hit statistical significance.
Market UnderappreciationShares are believed to have the potential to trade up significantly under the bull case scenario, which is not fully appreciated by the market.
---
Ownership Overview
0.57% Insiders
26.31% Mutual Funds
0.31% Other Institutional Investors
60.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RYTM FAQ
What was Rhythm Pharmaceuticals’s price range in the past 12 months?
Rhythm Pharmaceuticals lowest stock price was $35.17 and its highest was $68.58 in the past 12 months.
What is Rhythm Pharmaceuticals’s market cap?
Rhythm Pharmaceuticals’s market cap is $3.15B.
When is Rhythm Pharmaceuticals’s upcoming earnings report date?
Rhythm Pharmaceuticals’s upcoming earnings report date is May 06, 2025 which is in 32 days.
How were Rhythm Pharmaceuticals’s earnings last quarter?
Rhythm Pharmaceuticals released its earnings results on Feb 26, 2025. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.694 by -$0.026.
Is Rhythm Pharmaceuticals overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals’s price is currently Undervalued.
Does Rhythm Pharmaceuticals pay dividends?
Rhythm Pharmaceuticals does not currently pay dividends.
What is Rhythm Pharmaceuticals’s EPS estimate?
Rhythm Pharmaceuticals’s EPS estimate is -0.68.
How many shares outstanding does Rhythm Pharmaceuticals have?
Rhythm Pharmaceuticals has 63,223,730 shares outstanding.
What happened to Rhythm Pharmaceuticals’s price movement after its last earnings report?
Rhythm Pharmaceuticals reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.694. Following the earnings report the stock price went up 4.488%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals?
Currently, no hedge funds are holding shares in RYTM
---
Rhythm Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.18 (44.69% Upside)
$75.18 (44.69% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.83%
12-Months-Change
Fundamentals
Return on Equity
-272.15%
Trailing 12-Months
Asset Growth
18.25%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
---
RYTM Company Deck
---
RYTM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with strong financial positioning, robust sales growth, and significant pipeline advancements. However, there are concerns about high operating expenses and potential challenges in market uptake for new indications.Read More>---
RYTM Stock 12 Month Forecast
Average Price Target
$75.18
▲(44.69% Upside)
Technical Analysis
Seres Therapeutics
―
Crinetics Pharmaceuticals
―
Akero Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Best Analysts Covering RYTM
1 Year
1 Year Success Rate
14/16 ratings generated profit
1 Year Average Return
+55.05%
reiterated a buy rating 4 months ago
Copying Corinne Johnson's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +55.05% per trade.
---